Cost-Minimization Analysis of Panitumumab Compared with Cetuximab in the First-Line Treatment of Wild-Type RAS Metastatic Colorectal Cancer Patients in Brazil

Cancer Patients ◽

Cost Minimization ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Cost-Minimization Analysis of Bevacizumab Verse Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer in Kras Wild-Type Patients in the Supplementary Health Care System in Brazil

Value in Health ◽

10.1016/j.jval.2014.08.2311 ◽

2014 ◽

Vol 17 (7) ◽

pp. A641

Author(s):

C.T. Tsuchiya ◽

H.S.J. Kim ◽

M.F.M. Maximo ◽

L.A. Ramos

Keyword(s):

Colorectal Cancer ◽

Health Care ◽

Health Care System ◽

Cost Minimization ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2018.03.003 ◽

2018 ◽

Vol 125 ◽

pp. 69-77 ◽

Cited By ~ 6

Author(s):

Domenico Ciliberto ◽

Nicoletta Staropoli ◽

Francesca Caglioti ◽

Silvia Chiellino ◽

Antonella Ierardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Cost-Minimization Analysis of Bevacizumab Compared to Cetuximab and Panitumumab in First-Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer in France

Value in Health ◽

10.1016/j.jval.2016.09.2238 ◽

2016 ◽

Vol 19 (7) ◽

pp. A738

Author(s):

A Gherardi ◽

C Masia ◽

N Plommet

Keyword(s):

Colorectal Cancer ◽

Cost Minimization ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild type metastatic colorectal cancer in the United States

Journal of Medical Economics ◽

10.1080/13696998.2021.1982181 ◽

2021 ◽

pp. 1-1

Author(s):

Wambui Grace Gathirua-Mwangi ◽

Harsheen Sethi ◽

Manuel Geroy Afable ◽

Devarshi Bhattacharyya ◽

Taha Khan

Keyword(s):

Colorectal Cancer ◽

United States ◽

Cost Minimization ◽

The United States ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Faculty of 1000 evaluation for FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718009648.793485773 ◽

2013 ◽

Author(s):

Yiqian Nancy You ◽

Craig Messick

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox as a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece

Value in Health ◽

10.1016/j.jval.2014.08.2268 ◽

2014 ◽

Vol 17 (7) ◽

pp. A633 ◽

Cited By ~ 2

Author(s):

G. Kourlaba ◽

I. Boukovinas ◽

Z. Saridaki ◽

V. Papagiannopoulou ◽

G. Tritaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Annals of Oncology ◽

10.1093/annonc/mdt165 ◽

2013 ◽

Vol 24 (8) ◽

pp. 2062-2067 ◽

Cited By ~ 67

Author(s):

L. Fornaro ◽

S. Lonardi ◽

G. Masi ◽

F. Loupakis ◽

F. Bergamo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Annals of Oncology ◽

10.1093/annonc/mdw335.14 ◽

2016 ◽

Vol 27 ◽

pp. iv43

Author(s):

D. Rossini ◽

M. Casagrande ◽

R. Moretto ◽

F. Loupakis ◽

C. Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Pooled Analysis ◽

Line Treatment ◽

Targeted Agents ◽

First Line ◽

Safety And Efficacy ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

Colorectal Cancer Patients

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽